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CD133+ populations of human glioblastoma multi-
forme (GBM) cells are reportedly enriched for tumor
stem cells (TSCs) or tumor-initiating cells (TICs).
Approximately 40% of freshly isolated GBM speci-
mens, however, do not contain CD133+ tumor cells,
raising the possibility that CD133 may not be
a universal enrichment marker for GBM TSCs/TICs.
Here we demonstrate that stage-specific embryonic
antigen 1(SSEA-1/LeX)+ GBM cells fulfill the func-
tional criteria for TSC/TIC, since (1) SSEA-1+ cells
are highly tumorigenic in vivo, unlike SSEA-1- cells;
(2) SSEA-1+ cells can give rise to both SSEA-1+
and SSEA-1 cells, thereby establishing a cellular
hierarchy; and (3) SSEA-1+ cells have self-renewal
and multilineage differentiation potentials. A distinct
subpopulation of SSEA-1+ cells was present in all but
one of the primaryGBMsexamined (n = 24), andmost
CD133+ tumor cells were also SSEA-1+, suggesting
that SSEA-1 may be a general TSC/TIC enrichment
marker in human GBMs.
INTRODUCTION
The cancer stem cell hypothesis posits that tumorigenic poten-
tial is largely restricted to a subset of self-renewing tumor cells
with stem cell-like properties designated as tumor stem cells
(TSCs) or tumor-initiating cells (TICs) (Clarke et al., 2006; Jordan
et al., 2006; Reya et al., 2001). Since these TSCs/TICs represent
only a subpopulation within the whole of the tumor, there is great
interest in finding cell-surface markers that will allow the
prospective identification and isolation of these cells (Uchida
et al., 2000; Vescovi et al., 2006). The AC133 (later designated
as CD133/PROM1) antigen was originally identified as a surface
antigen expressed in hematopoietic stem cell populations
(Corbeil et al., 1998; Miraglia et al., 1997). Weissman and
colleagues have shown that human fetal brain cells expressing
AC133 antigen have neural stem cell (NSC)-like properties
(Uchida et al., 2000). Several groups have demonstrated that
cell sorting for CD133 expression can enrich for TSC/TIC
populations in brain tumors (Bao et al., 2006; Galli et al., 2004;440 Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc.Piccirillo et al., 2006; Singh et al., 2004) as well as in colon cancer
(O’Brien et al., 2007; Ricci-Vitiani et al., 2007) and prostate
cancer (Richardson et al., 2004). These CD133+ cells appear
to be responsible for tumor initiation in vivo and are relatively
resistant to radiation compared to the remaining bulk of tumor
cells, suggesting their potential role in tumor recurrence (Bao
et al., 2006).
Whether CD133 can serve as a universal TSC enrichment
marker for all tumors, however, has been questioned following
a series of recent papers. Several groups have reported the
absence of CD133+ cell populations in primary GBM-derived
cells (Beier et al., 2007; Joo et al., 2008; Ogden et al., 2008;
Wang et al., 2008). Similarly, it has been proposed that CD44
can be an enrichment marker for colon and prostate cancer
TICs (Dalerba et al., 2007; Patrawala et al., 2007). In these
studies, tumor cells expressing both CD133 and CD44 cells
were not a significant population (Dalerba et al., 2007; Shmelkov
et al., 2008), suggesting that there may exist more than one
marker that can prospectively enrich for a TSC/TIC population.
Alternatively, it is also possible that TSC/TIC population may
not exist in some tumors. Indeed, two groups have provided
evidence that almost all tumor cells can function as TSCs/TICs
in lymphoma and human melanoma (Kelly et al., 2007; Quintana
et al., 2008). Determining whether these two possibilities exist in
human GBMs has significant biologic and clinical implications.
Over the last few years, we have been isolating TSC/TIC-like
cells from various primary GBMs by culturing freshly dissociated
GBM cells from patients in media favoring the growth of normal
NSCs (Lee et al., 2006; Lee et al., 2008). In nearly half of these
in vitro-established TSC/TIC lines, as well as acutely isolated
tumor cells from fresh GBM patient tumors (total of 24 samples),
we failed to detect a distinct CD133+ populations. Nevertheless,
these ‘‘CD133-negative’’ tumors contain cells with stem cell-like
properties that are highly tumorigenic in orthotopic transplanta-
tion SCIDmodels, similar to CD133+ TSC/TIC lines fromCD133+
tumors. In search of an alternative and/or more general enrich-
ment marker for GBM TSCs/TICs, we have identified distinct
subpopulations of cells expressing a neural stem/progenitor
cell marker, stage-specific embryonic antigen 1 (SSEA-1/
CD15/Lewis X [LeX]) (Capela and Temple, 2002, 2006). We
now demonstrate that the selection for SSEA-1+ cells enriches
for glioma TSC/TIC subpopulations in all of the GBMs that are
devoid of CD133+ cells. These SSEA-1+ cells give at least
a 100-fold tumorigenic enrichment in mouse xenograft models
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renewal and multilineage differentiation. We propose that
SSEA-1, along with CD133, is a marker that enriches for TSCs/
TICs in primary human GBMs.
RESULTS
Expression of SSEA-1 in Acutely Isolated GBM Cells
and Established TSC/TIC Lines
We have established TSC/TIC-like cells from various primary
GBMs by culturing freshly dissociated cells in neurobasal
serum-free media with N2/B27 supplement in the presence of
basic FGF and EGF (NBE media) (Lee et al., 2006, 2008). We
have used rather strict criteria for defining TSC/TIC lines,
requiring that they are clonogenic in vitro, express stem cell
markers, be capable of neuronal and/or glial differentiation, be
tumorigenic in vivo in serial transplantation, and be able to
generate xenograft tumors that recapitulate the biological and
genomic features of the parental GBM.
In an attempt to phenotype various established TSC/TIC lines,
we first determined the expression of CD133 by fluorescence-
activated cell sorting (FACS) analysis (Table 1 and Figure 1). We
found that seven cell lines out of 12 different GBM TSC/TIC lines
hadverydistinct subpopulationsofCD133+cells. Thepercentage
of CD133+ cells ranged from 1.7% to 63.5% (Table 1), similar to
what has been previously reported (Piccirillo et al., 2006; Singh
et al., 2004). By contrast, the remaining five cell lines did not
contain any cells with detectable levels of CD133 expression,
consistent with other reports (Beier et al., 2007; Joo et al., 2008;
Ogden et al., 2008; Wang et al., 2008). Similar to the GBM lines
containing CD133+ cells, these cell lines are highly tumorigenic,
grew as neurospheres (see Figure S1A available online), and ex-
pressed high levels of stemcell-associated proteins such asNes-
tin (Lendahl et al., 1990), Sox2 (Suh et al., 2007; Yuan et al., 1995),
Bmi1 (LessardandSauvageau,2003), andEzh2 (Shenetal., 2008;
Sher et al., 2008; Valk-Lingbeek et al., 2004) (Figure S1C). These
data, which are consistent with those of others (Beier et al.,
2007; Joo et al., 2008; Ogden et al., 2008; Wang et al., 2008),
suggest that CD133 may not be a universal enrichment marker
for TSC/TIC in GBMs.
In order to identify a potential general TSC/TIC enrichment
marker(s) applicable to most GBMs, we first screened several
surfaceantigensexpressedonnormalNSCs.Onesuchcandidate
molecule was SSEA-1/LeX. We identified distinct SSEA-1+ cell
populations in all but one established TSC/TIC line (11 of 12 cell
lines in total, the 0211 line being the only exception). In addition,
we determined the expression level of SSEA-1 in acutely isolated
GBM tumor cells that were not passaged in vitro. Acutely isolated
tumor cells from all tested GBMs contain distinct SSEA-1+ popu-
lations (26.6% ± 26.3%), suggesting universal expression of
SSEA-1 in GBMs (Table 1). In order to determine whether these
SSEA-1+ cells exist in human GBMs in situ, we performed immu-
nohistochemical analysis of patient-derived GBM paraffin
sections (Figure 1). Consistent with the in vitro data, a subpopula-
tion of cells with distinct cell membrane-associated staining was
detected in GBM patient paraffin sections (Figure 1A). The one
GBM in which we did not find SSEA-1+ staining was the tumor
from which the only SSEA-1 TSC/TIC line was derived (0211
cells), adding credibility to both the fidelity of antibody stainingand the consistency of SSEA-1 status in early passage cells and
the primary tumor (Figure 1A). By contrast, we could not obtain
reliable immunohistochemical staining of CD133 despite multiple
trials usingdifferent antibodiesandmodificationof staining condi-
tions (data not shown).
Next, we performed CD133/SSEA-1 dual FACS staining of the
TSC/TIC lines in order to determine whether there is significant
overlap between these subpopulations (Figure 1B and Table 1).
In six out of seven established TSC/TIC lines containing CD133+
cells, a significant proportion of CD133 cells (67.8% ± 22.1%)
was also positive for SSEA-1. The percentages of SSEA-1+
and CD133+ cells were widely variable between different
GBMs; however, more than 95% of GBMs contained SSEA-1+
cells, regardless of the presence of CD133+ cells (Table 1).
In Vitro Characterization of SSEA-1+ Cells from Various
GBM-Derived TSCs/TICs
It was reported that CD133 expression in the brains, determined
by immunohistochemical staining of AC133 antibodies, is
restricted to the early fetal stages but absent in adult brains
including in the subventricular zone (SVZ), where NSCs reside
(Pfenninger et al., 2007). Two recent papers, however, have re-
ported broad expression of CD133mRNA in the brains of embry-
onic and adult CD133 promoter knockin mice (Shmelkov et al.,
2008; Zhu et al., 2009). Whether these data are applicable to
the human and whether mRNA expression correlates with immu-
nopositivity of CD133 antibodies that recognize glycosylation-
dependent epitopes remain unanswered questions (Coskun
et al., 2008; Mirzadeh et al., 2008; Shmelkov et al., 2008; Uchida
et al., 2000; Zhu et al., 2009). By contrast, SSEA-1 expression is
persistent throughout most stages of neural development and in
the adult SVZ (Capela and Temple, 2002, 2006). Thus, given the
frequency of SSEA-1 expression in GBMs, we chose to further
characterize the SSEA-1+ subpopulation from various GBM-
derived TSCs/TICs.
First, we determined the clonogenicity of the SSEA-1+ versus
the SSEA-1 subpopulation from various GBM-derived TSCs/
TICs in vitro. SSEA-1-dependent cell sorting was performed
using FACS, followed by confirmation of the purity of the sepa-
rated cell populations (SSEA-1+, 79.3%–96.7%; and SSEA-1,
98.0%–99.7%) and their viability. SSEA-1+ cells derived from
three different GBM lines were consistently more clonogenic
than their respective SSEA-1 cells in a standard soft-agar
colony-forming assay (Figure 2A) and limiting dilution assay
(Figure 2B). Additionally, PCNA staining and cell-cycle analysis
revealed that SSEA-1+ cells have significantly more PCNA stain-
ing (Figure 2C) and a much larger S/G2/M phase population
(Figure 2D) than do SSEA-1 cells. Taken together, these data
indicate that SSEA-1+ cells are enriched for cells actively
traversing the cell cycle with clonogenic potential.
Second, we determined whether the SSEA-1+ subpopulation
is enriched for cells expressing stem cell-associated markers by
Western blot analysis (Figure 3). We fractionated GBM cells
maintained in NBE condition by the expression status of
CD133 or SSEA-1 (Figure 3A). CD133- or SSEA-1-dependent
cell sorting was performed by using immunomagnetic selection,
followed by FACS confirmation of the purity (higher than 90%)
and the viability of sorted populations. Consistent with the
previous reports (Bao et al., 2008; Ligon et al., 2007; Liu et al.,
Table 1. Expre
cent Expression of Xenograft Tumors
al
33+
Total
SSEA-1+
CD133+/
SSEA-1+
SSEA-1+
in CD133+
(1) Established
TSC/TIC Lines
± 6.5 17.6 ± 14 2.5 ± 2.9 19.8 ± 16.3
± 0.2 63.5 ± 13.6 3.4 ± 0.4 97.7 ± 14.6
± 0.4 38.3 ± 8.5 1.5 ± 0.1 65.8 ± 6.0
± 1.0 31.2 ± 9.3 1.2 ± 1.1 40.2 ± 24.8
ND ND ND
ND ND ND
± 13.3 0 0 0
8.8 ± 4.3 0 0
3.1 ± 1.7 0 0
2.8 0 0
56.9 ± 27.3 0 0
ND ND ND
(2) Freshly
Isolated
GBM Cells
GBM tumor lines cells isolated from primary patient GBMs that
have not been ex rmined only in later passages in some of the
established GBM SEA-1 was determined at various passages
during the in vitro in the whole population. ‘‘CD133+/SSEA-1+’’
indicates the per ut of the CD133+ cells. ND, not determined.
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.ssion of CD133 and/or SSEA-1 in Various Primary Human GBMs and Their Derivative Tumor Cells
Percent Expression at the Earliest Passages Percent Expression during In Vitro Expansion Per
TSC
Name
Total
CD133+
Total
SSEA-1+
CD133+/
SSEA-1+
SSEA-1+
in CD133+ Passages
Total
CD133+
Total
SSEA-1+
CD133+/
SSEA-1+
SSEA-1+
in CD133+ Passages
Tot
CD1
0308 38.2 57.9 17.3 45.3 p5 22.2 ± 6.5 60.1 ± 17.5 12.0 ± 1.5 56.5 ± 12.3 p10–13 10.2
0206 3.7 87.5 3.2 86.5 P2 7.4 ± 1.3 64.7 ± 22.0 6.6 ± 1.3 89.2 ± 1.4 p5–7 3.5
0827 2.1 74.4 2.0 95.2 P1 2.4 ± 2.5 46.0 ± 8.4 1.2 ± 1.2 50.2 ± 3.1 p2–6 2.3
1031 1.7 1.0 ND ND P0 9.4 ± 8.4 52.4 ± 20.7 7.9 ± 8.4 74.2 ± 23.2 p8–10 2.7
0822 63.5 85.8 60.4 95.1 P4 57.3 ± 15.5 87.6 ± 7.3 54.8 ± 14.0 95.8 ± 1.5 p11–12 ND
0117 22.3 7.7 2.5 11.2 P4 5.7 ± 0.7 45.0 ± 16.7 2.3 ± 0.5 41.0 ± 3.5 p14–15 ND
0211 28.0 0 0 0 p7 34.6 ± 10.8 0 0 0 p7–15 33.8
1228 0 6.8 0 0 p3 0 41.9 ± 9.0 0 0 p7–19 0
0131 0 3.4 0 0 p3 0 2.5 ± 1.9 0 0 p8–14 0
0707 0 0.7 0 0 p5 0 3.5 ± 1.3 0 0 p6–10 0
0905 0 56.6 0 0 p1 0 86.6 ± 16.6 0 0 p2–8 0
0909 0 3.0 0 0 p1 0 94.2 0 0 p2 ND
1106 10.8 18.1 7.9 73.1 p0
K4 5.2 5.6 3.9 75.0 p0
447 10.4 70.5 6.7 64.2 p0
492 12.4 10.8 2.4 18.9 p0
453 8.5 18.7 5.3 62.3 p0
460 6.6 70.3 4.9 74.5 p0
1218 0 13.4 0 0 p0
449 0 5.9 0 0 p0
461 0 32.2 0 0 p0
0605 0 2.4 0 0 p0
0420RP 0 63.3 0 0 p0
475 0 7.7 0 0 p0
were presented as two groups: (1) the established TSC/TIC lines that have been expanded in vitro and (2) acutely dissociated tumor
panded in culture (labeled as passage 0 [p0]). Due to the limited number of cells, the expression of CD133 and/or SSEA-1 was dete
lines. We reported the expression values at the earliest passage technically possible in these cases. Expression of CD133 and/or S
expansion phase as well as the xenograft tumors. ‘‘Total CD133+’’ or ‘‘Total SSEA-1+’’ indicates the percentage of the positive cells
centage of double-positive cells in the whole population. ‘‘SSEA-1+ in CD133+’’ indicates the percentage of double-positive cells o
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Figure 1. Expression of SSEA-1 in Primary Human GBM Tissues and Their Derivative TSCs/TICs
(A) Immunohistochemical detection of SSEA-1 and Sox2 in paraffin section from four different patient GBM tissues. Immunopositive cells were visualized by
brown DAB staining. The number above represents the designated name for the parental patient GBM tumor. Scale bar represents 20 micron.
(B) Flow cytometry analysis of CD133 (PE labeled, y axis) and SSEA-1 (FITC labeled, x axis) in various TSCs/TICs. Numbers in each quadrate indicate percentage
of cells.Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc. 4432006; Singh et al., 2004), CD133+ populations revealed higher
expression of various stem cell-associated markers. Similar to
CD133+ populations, SSEA-1+ subpopulations showed higher
levels of stem cell marker expression including SOX2 (Yuan
et al., 1995), Bmi1 (Lessard and Sauvageau, 2003), Ezh2 (Lee
et al., 2008; Valk-Lingbeek et al., 2004), L1CAM (Bao et al.,
2008), and Olig2 (Ligon et al., 2007) compared to respective
negative populations (Figure 3A).
Others and we have previously demonstrated that GBM TSCs/
TICs have the potential to differentiate along glial and/or neuronal
lineageswithconcurrent lossof stemcellmarker expression (Galli
et al., 2004; Lee et al., 2006, 2008; Singh et al., 2004). In order to
determine whether SSEA-1+ cells have such differentiationpotential, we performed immunocytochemical analysis by using
various GBM TSC/TIC lines cultured in the absence of FGF2/
EGF or in the presence of serum. Under these differentiation-
inducing conditions, SSEA-1-expressing neurosphere cells
underwent significant morphological changes, including exten-
sionof processes andspread-out cell shapes (Figure 3B). In order
to determine the relative expression of stem cell and differentia-
tion markers during differentiation, we processed these cells for
immunocytochemical analysis and quantitated immunopositive
cells (Figure 3C and Figure S2). The differentiation conditions
induced significantly increased expression of the astroglial differ-
entiationmarkersGFAP/S100b and/or the neuronalmarker TuJ1,
with concurrent loss of the stem/progenitor cell markers such as
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Figure 2. Characterization of SSEA-1+ and SSEA-1 Cells In Vitro from Various GBM-Derived TSCs/TICs
(A) Soft agar colony-forming assay to determine clonogenicity of SSEA-1+ versus SSEA-1 cells from three different GBM lines.
(B) Limiting dilution sphere-forming assay. Three cell lines used in (A) were plated into 96-well plates with various seeding densities (5–50 cells per well, 30 wells
per each condition). Data from a representative experiment were shown. R2 > 0.83.
(C and D) PCNA staining (C) and cell-cycle analysis (D) of 1228 and 0131 cells by flow cytometry. Error bars represent SD (performed in triplicates); *p < 0.05.Sox2 and Nestin. Similar to other stem/progenitor cell markers,
SSEA-1 expression was significantly decreased under differenti-
ation conditions (Figure 3C).
We also examined whether SSEA-1+ cells expressed other
proposed neural stem/progenitor cell markers. Integrin alpha6,
Integrin beta1 (Hall et al., 2006), and Olig2 have been reported
to be highly expressed in normal NSCs and progenitor cells. In
GBMs, it has been reported that most CD133+ cells are also
Olig2+ (Ligon et al., 2007). Most SSEA-1+ TSC/TIC cells were In-
tegrin beta1+ under NBE conditions with significant downregula-
tion of both Integrin beta1 and SSEA-1 under differentiation
condition (absence of FGF2/EGF) (Figure S3). Similar to Integrin
beta1, Integrin alpha6 andOlig2-expressing cells were alsomore
enriched in SSEA-1+ cells under NBE conditions. Moreover,
most of SSEA-1+ cells were Integrin alpha6+ (84%), beta1+
(94%), and Olig2+ (75%), and their expressions were signifi-
cantly decreased under differentiation conditions (Figure S3).
Taken together, these data suggest that SSEA-1+ cells express
stem cell-associated markers and can differentiate toward
a more mature phenotype.
In order to address the cellular hierarchy of SSEA-1+ glioma
cells, we performed lineage-tracking experiments (Figure 4).
GBM TSCs/TICs were transduced with lentiviral vectors ex-
pressing red fluorescence protein (RFP) or green fluorescence
protein (GFP). Genetically labeled SSEA-1 + cells (expressing
RFP) and SSEA-1 cells (expressing GFP) were mixed in various
ratios and cultured at low-cell density allowing for clonal expan-
sion. After 2 weeks of culture, the remaining cells were examined444 Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc.for GFP/RFP expression aswell as SSEA-1 expression (Figure 4).
Even in the wells in which only 5% of the initial cells were ex-
pressing RFP, most of the sphere-forming and SSEA-1+ cells
after 2 weeks of cultures were RFP+, indicating that these cells
were derived from SSEA-1+ cells (Figure 4C). Additionally,
secondary sphere formation assay was performed to further
compare relative clonogenicity of SSEA-1+ and SSEA-1 cells.
Almost all secondary spheres were originated from SSEA-1+
cells (Figure 4A). Similar results were obtained from nongenetic
labeling methods (Figure S4). Taken together, these data
strongly indicate that SSEA-1+ GBM cells are highly clonogenic
and sustain in vitro growth of the total tumor cell population by
generating both SSEA-1+ and SSEA-1 cells.
Tumorigenic Potential of SSEA-1+ Cells in SCID
Orthotopic Transplantation Model
In order to determine whether the subpopulation of SSEA-1+
cells is enriched for tumorigenic potential in vivo, we injected
magnetic bead-sorted SSEA-1+, SSEA-1, and unsorted cells
into the brains of neonatal NOD-SCID mice (Figure 5). Cells
from four different GBMs were evaluated for tumorigenic poten-
tial of SSEA-1+ subpopulations. Acutely isolated (i.e., without
in vitro expansion) SSEA-1+ cells from fresh GBM tissues gener-
ated tumors significantly more efficiently than SSEA-1 cells
(Figure 5A). We also evaluated the tumorigenic potential of
SSEA-1+ cells derived from in vitro-established TSC/TIC lines.
Only unsorted and SSEA-1+ cells consistently formed tumors
in mice, whereas SSEA-1 cells failed to generate tumors.
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Figure 3. SSEA-1+ Cells Express a High Level of Stem Cell-Associated Proteins and Have Differentiation Potentials In Vitro
(A) Expression of stem cell-associated proteins in CD133+/ or SSEA-1+/ subpopulation from four different GBM lines. Cells cultured in NBEmedia were sepa-
rated into two groups either by CD133 or by SSEA-1, and then proteins were extracted forWestern blot analysis. a-tubulin was used as a loading control. Note the
absence of CD133 protein expression in 1228 and 0905 lines.
(B) Immunocytochemical analysis of 0905 GBM line cultured in differentiation-inducing condition. Each column represents the same culture condition. ‘‘FGF2+
EGF’’ indicates the NBE condition used in the proliferation of these cells. ‘‘–’’ and ‘‘serum’’ indicate the growth factor withdrawal and the addition of serum,
respectively. Antibodies used in each condition are shown below. DAPI staining (blue) was used to identify nuclei. White bars represent 50 micron.
(C) Quantitation of immunopositive cells in (B). Error bars represent SD; *p < 0.01.Importantly, the onset of tumors was significantly faster, and the
overall survival of tumor-bearing animals was significantly
shorter in SSEA-1+ cell-injected mice than in mice injected
with unsorted cells (Figure 5B). Next, in order to estimate the
relative enrichment of tumorigenic potential in SSEA-1+ cells
compared to SSEA-1 cells, we performed additional in vivo
tumorigenicity titration assays by varying the number of injected
1228 cells (Figure 5C). As few as 1000 SSEA-1+ cells were
enough to initiate tumors, whereas 300,000 cells of SSEA-1
cells were required to make occasional tumors (two out of nine
mice after 12 months of injection). The cell numbers required
for tumor generations in SSEA-1 cells were more than two
orders of magnitude greater, suggesting that SSEA-1+ cells
are more than 100-fold enriched for tumorigenic potential. In
order to provide definite evidence of enriched tumorigenic
potential of SSEA-1+ cells, we performed in vivo lineage-tracing
experiments by using genetically labeled SSEA-1+ cells (RFP
transduced) and SSEA-1 cells (GFP transduced) (Figure 5D).Even in the situation in which only 1% of RFP-expressing cells
was mixed with 99% GFP-labeled SSEA-1 cells and then in-
jected into the brains of adult SCID mice, the resultant tumors
were composed almost entirely of RFP-expressing cells.
Furthermore, the SSEA-1+ cells from these tumors sustained
their tumorigenic potential in serial transplantation experiments
in which SSEA-1+ cells from xenograft tumors were isolated by
sorting and then transplanted back into the brains of secondary
mice (Figure 5E). Taken together, these data demonstrate that
SSEA-1+ cells are highly enriched in tumorigenic potential and
are capable of forming secondary tumors following in vivo
passage.
In order to determine the fate of these injected SSEA-1+ and
SSEA-1 tumor cells well before the formation of apparent
tumor masses, we performed immunohistochemical analysis
using a human-specific antibody. We detected distinct human
tumor cells infiltrating widely into brain parenchyma and adja-
cent to the ventricular walls of mice injected with SSEA-1+ cells.Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc. 445
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Figure 4. Lineage Tracking of SSEA-1+ versus SSEA-1 GBM Cells
(A) Representative microphotograph of the resultant cells that were cultured for 2 weeks after the mixture of 0905-derived SSEA-1+ (red) and SSEA-1 (green) at
the indicated ratios. Cells were harvested at a 2 week time point and prepared for secondary sphere-forming assay (the bottom row) or quantitation by flow
cytometry (B). These cells were further stained with SSEA-1-PE antibody, and the representative data from the mixture of 5% SSEA-1+ and 95% SSEA-1 cells
are shown (C). Spheres generated after the initial 2 week cultures were counted in each condition (D). Error bars represent SD; *p < 0.05.By contrast, there were significantly fewer human cells in brains
injected with SSEA-1 cells (Figure S5).
Characterization of SSEA-1+ Cells in SCID Xenograft
Tumors In Situ
If the SSEA-1+ population of cells has TSC/TIC properties
in vivo, one would expect that SSEA-1+ cells would persist446 Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc.and retain stem cell-like properties in tumors generated by
both unsorted and SSEA-1+ GBM-derived cells. We therefore
determined the SSEA-1 expression of cells acutely dissociated
from these xenograft tumors. Similar to the parental tumor,
tumor xenografts derived from SSEA-1+ cells displayed a
mixture of both SSEA-1+ cells and SSEA-1 cells, demonstrat-
ing the ability of SSEA-1+ cells to generate both SSEA-1+ and
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Figure 5. In Vivo Tumorigenic Potential of SSEA-1+ Cells in SCID Mouse Orthotopic Xenograft Models
(A) Kaplan-Maier survival graphs of animals injected with total (unsorted), SSEA-1+, or SSEA-1 population of acutely isolated GBM cells (1031) at passage zero.
(B) Kaplan-Maier survival graphs of 1228, 0420 RP, and 0131 GBM cells (from left to right). P values were determined by log rank test: p < 0.01.
(C) In vivo tumorigenicity titration of SSEA-1+ versus SSEA-1 1228 GBM cells. Tumorigenic potential of subpopulation was evaluated by the tumor formation
rate.
(D) Lineage tracking of SSEA-1+ versus SSEA-1 GBM cells in vivo. GFP-transduced SSEA-1 cells and RFP-transduced SSEA-1+ GBM cells were mixed at
100: 0 (upper) and 99: 1 ratio (lower) and injected into the brains of adult SCID mice. Immunofluorescence microphotographs were taken to detect GFP and RFP.
DAPI (blue) was used to visualize nuclei.
(E) Representative microphotograph of secondary tumor xenograft induced by serial transplantation of SSEA-1+ 1228 GBM cells. Scale bars represents
100 micron.Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc. 447SSEA-1- cells in vivo, as we had demonstrated in vitro (Figure 6A
and Table 1). Since it is technically possible that we could have
missed a rare subpopulation of CD133+ cells in our initial
tumor-inducing cell population, we also examined these xeno-
graft tumors for the expression of CD133+ cells. Importantly,
we could not find any CD133+ cells in any of our xenograft tumor
cells (Figure 6A and Figure S6). Thus, these data further support
the notion that SSEA-1+ cells function as TICs in these CD133
GBM tumors.
In order to further characterize the tumor cells within the xeno-
graft tumors, we performed clonogenicity assay, PCNA staining,
and cell-cycle analysis by using freshly dissociated cells from
xenograft tumors (Figures 6B–6E). All SSEA-1+ cells isolated
from three different TSC/TIC line-derived xenograft tumors
were highly clonogenic compared to their respective SSEA-1
counterparts (Figures 6B and 6C), similar to our in vitro data
(Figures 2A and 2B). SSEA-1+ cells acutely isolated from
xenograft tumors had significantly greater PCNA staining
(Figure 6D) and a larger S/G2/M phase population (Figure 6E)than did SSEA-1 cells, indicating the higher proliferation poten-
tial of SSEA-1+ cells in vivo. Furthermore, SSEA-1+ cells main-
tained high-level expression of the stem cell markers compared
to the SSEA-1 cells, as determined by comparative flow
cytometry (Figure 6F). In sum, these data implicate that in vivo
SSEA-1+ cells are highly clonogenic and proliferative and
express markers consistent with a TSC/TIC phenotype.
DISCUSSION
Early reports suggested that CD133 expression was synony-
mous with, or at least a prerequisite for, glioma-derived TSCs/
TICs (Bao et al., 2006; Dirks, 2006; Piccirillo et al., 2006; Singh
et al., 2004; Trumpp and Wiestler, 2008). More recent reports,
however, have suggested that CD133 may not be an absolute
indicator of such cells (Beier et al., 2007; Bidlingmaier et al.,
2008; Griguer et al., 2008; Joo et al., 2008; Wang et al., 2008).
These apparent discrepancies in the literature could be
explained in part by poor reliability of antibodies detecting
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Figure 6. Characterization of SSEA-1+ Cells in SCID Xenograft Tumors In Situ
(A) FACS analysis to determine the percentage of cells expressing CD133 and/or SSEA-1. Cells prepared for the injection into mice (Aa) and isolated from the
resultant xenograft tumors (Ab) were used for the analysis. As a representative example, data from 1228 line were shown. Soft agar colony-forming assay (B) and
limiting dilution sphere forming assay (C) were performed in order to determine clonogenicity of SSEA-1+ versus SSEA-1 cells that were acutely isolated from
xenograft tumors. These three different tumors were derived from injection of three different GBM lines (1228, 0905, and 0131), respectively. R2 > 0.94. PCNA
staining (D) and cell-cycle analysis (E) of xenograft tumors derived from 1228 and 0131 cells were performed by flow cytometry. (F) Expression of stem cell-related
genes in SSEA-1+ versus SSEA-1 population of xenograft tumor cells, determined by FACS staining. The tumors were generated by the injection of 1228
SSEA-1+ cells. Error bars represent SD (performed in triplicates); *p < 0.05.448 Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc.
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2002) and/or the recent observation that expression of CD133
itself may be reversibly modulated by environmental factors
such as hypoxia and cellular stress (Chen et al., 2007; Griguer
et al., 2008). Another possibility, however, is that CD133 is not
a universal marker for TSCs/TICs in every GBM cell.
Although CD133+ GBM cells meet the functional criteria of
TSCs/TICs, we have found that approximately 40% of exten-
sively analyzed glioblastomas did not contain CD133+ cells
either upon immediate tumor dissociation or during in vitro cell
expansion under stem cell culture conditions. Nevertheless,
these CD133 GBMs still harbor a subpopulation of TSCs/
TICs cells as defined by their ability to generate neurospheres
in culture; capability of bilineage differentiation; clonogenicity
in soft agar; and ability to form highly invasive, malignant, and
serially transplantable tumors in immunodeficient animals.
In order to enrich for the presumptive subpopulation of TSCs/
TICs in the CD133 tumors, we reasoned that these cells might
express markers found on normal neural stem/progenitor cells.
Thus, alongwithother antigens,weevaluatedcells for theexpres-
sionof SSEA-1. The antigenSSEA-1, also knownasCD15or LeX,
is a fucose-containing trisaccharide highly expressed on embry-
onic stemcells in the developing brain and adult SVZ (Capela and
Temple, 2002, 2006). SSEA1+ cells exist throughout the major
developmental stages of the central nervous system, and their
relative abundance correlates well with the prevalence of neural
stem/progenitor cells (Capela and Temple, 2002, 2006). Consis-
tent with the persistent expression of SSEA-1 throughout devel-
opmental phases of the CNS, we found SSEA-1 expression in
TSC/TIC lines from 23 of 24 evaluated tumors (96%), whereas
only 13 of 24 GBM tumors (54%) harbored CD133+ cells.
Not only was SSEA-1 expression seen in the majority of TSC/
TIC lines, but the selection of SSEA-1-expressing cells enriched
for a population of cells that specifically harbored the properties
that meet all criteria for TSCs/TICs. Thus, SSEA-1+ cells formed
neurospheres, were clonogenic in soft agar, could generate
GFAP+ and Tuj1+ cells following induction of differentiation,
and were highly tumorigenic in vivo. Furthermore, SSEA-1+ cells
could generate both SSEA-1+ and SSEA-1 cells in vitro and
in vivo, suggesting a hierarchical lineage and the ability to
generate tumors heterogeneous for SSEA-1 expression much
like the primary GBM tumors in situ. Finally, SSEA-1+ cells
sorted from these SSEA-1+ cell-generated orthotopic tumors
could successively generate secondary tumors with the exact
same characteristics as the primary tumor, thereby further con-
firming their identity as TSCs/TICs.
As is the case for CD133, SSEA-1 does not enrich for a popu-
lation of glioblastoma TSCs/TICs in every tumor, since one of our
TSC/TIC lines contains CD133+ cells but not SSEA-1+ cells.
Nevertheless, SSEA-1 should prove to be a useful enrichment
marker for TSCs/TICs frommost glioblastomas, especially those
that are CD133. Since the significant overlap exists between
CD133+ cells and SSEA-1+ cells, SSEA-1 can be useful as
a TSC/TIC enrichment marker in CD133+ cell-containing
GBMs aswell. Our preliminary data showed that in some of these
tumors, both SSEA-1-/CD133+ cells and SSEA-1+/CD133
cells are much more tumorigenic as compared to SSEA-1/
CD133 cells. Precise characterization of these subpopulations
merits further investigation.Through a series of eloquent experiments, Read and
coworkers recently demonstrated the existence of CD15+
tumor-propagating cells in an animal model of medulloblastoma
with the identification of CD15+ cells within a subset of human
medulloblastoma specimens (Read et al., 2009). Our results,
along with Read et al., suggest that CD15 (SSEA-1) can be
a general TSC/TIC enrichment marker in human brain tumors.
Additionally, our findings are solely based on primary human
glioblastoma specimens, rather than being based largely on
a brain tumor animal model, adding to the potential clinical rele-
vance.
Similar to hematopoietic stem cells, probably the most thor-
oughly characterized stem cell population, a combination of
markers will ultimately best define glioma TSCs/TICs (Dick,
2008; Kim et al., 2006; Weissman et al., 2001). Given the
complex genetic and epigenetic heterogeneity of GBMs, it is
unlikely that the expression of a single marker such as CD133
or SSEA-1 will define TICs in all tumors. Furthermore, if tumors
originate from stem/progenitor cells at different points along
the normal developmental pathway, TSCs/TICs from different
subsets of gliomas may have different immunophenotypes and
characteristic stem cell markers. Whether SSEA-1+ tumors
represent a specific subtype of glioblastomas compared to
CD133+ tumors is impossible to determine conclusively at this
point due to the relatively small numbers of the established cell
lines evaluated to date. Additionally, whether CD133 and/or
SSEA-1 have functional properties in TSCs/TICs is an important
question worthy of further study.
In conclusion, SSEA-1 appears to be an enrichment marker for
glioblastoma-derived TSCs/TICs fromCD133 tumors.Whether
SSEA-1+ glioblastomas represent a distinct subset of glioblas-
tomas compared to CD133+ tumors and whether there are addi-
tional markers that will further refine the identification of the
specific TSC/TIC remain to be seen. Finally, it will be interesting
to see whether SSEA-1 might represent a TSC/TIC marker for
malignancies other than brain tumors.
EXPERIMENTAL PROCEDURES
TIC Cultures
Following informed consent, tumor samples classified as glioblastoma, based
on the World Health Organization (WHO) criteria, were obtained from patients
undergoing surgical treatment at the National Institutes of Health (NIH) in
accordance with the appropriate Institutional Review Boards (Kleihues et al.,
2002). Within 1–3 hr after surgical removal, tumors were washed and enzymat-
ically dissociated into single cells. Red blood cells were removed by differential
centrifugation. Tumor cells were cultured in NBE media consisting of neuro-
basal media (Invitrogen), N2 and B27 supplements (0.5 3 each; Invitrogen),
and human recombinant bFGF and EGF (25 ng/ml each; R&D Systems). For
induction of differentiation, cells were cultured in NBE media without growth
factors or DMEM media (Invitrogen) with 10% fetal bovine serum (Invitrogen).
Uncoated plastic dishes were used for neurosphere formation assays of NBE
cells. For adherent culture of NBE cells, the plates were precoated with poly-
ornithine/laminin mixture (Invitrogen).
FACS Analysis
PatientGBM-andxenograft-derived tumorcells aswell as in vitro-culturedcells
were dissociated into single-cell suspensions and labeled with the following
antibodies: anti-CD133-PE (Miltenyi Biotec), SSEA-1-FITC (MMA clone, BD),
Sox2 (R&D Systems, MAB2018), Bmi1 (Upstate), Ezh2 (PharMingen), GFAP
(DAKO), Tuj1 (Covance), Integrin alpha6 (Chemicon), Integrin beta1-PE (R&D
Systems), and Olig2 (Santa Cruz Biotechnology, sc-48817) antibody. For theCell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc. 449
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10min. Concentrations of other antibodies and the staining conditionswere fol-
lowed per the manufacturers’ recommendations. For nonconjugated primary
antibodies,wesubsequently incubatedwithPE-or FITC-conjugatedsecondary
antibodies (BD).Antibodies againstmouse immunoglobulin conjugated toPEor
FITC were used as antibody isotype controls (BD). The stained cells were
analyzed on the FACS Vantage SE flow cytometer (BD).
Cell Sorting
For flow cytometric cell sorting, cells were dissociated into single-cell suspen-
sions and labeled with anti-SSEA-1-FITC antibody (BD) and/or anti-CD133-PE
antibody (Miltenyi Biotec). These labeled cells were then physically sorted
using the FACS Vantage SE flow cytometer (BD). Cell Quest Acquisition and
Analysis software (BD) was used to acquire and quantify the fluorescence
signal distributions and intensities from individual cells. For magnetic cell sort-
ing, single-cell suspensions were labeled with anti-SSEA-1-FITC antibody
(BD), incubated with anti-FITC microbeads (Miltenyi Biotec), and then sepa-
rated by using MACS separation system (Miltenyi Biotec). We have followed
the manufacturer’s protocol in these steps. In order to ensure high purity of
sorted populations, we have used two separation columns consecutively.
We confirmed the purity of cells by FACS analysis of tumor cells after cyto-
fluorimetric or magnetic sorting.
Soft Agar Colony-Forming Assay
The standard protocol was used with a minor modification. Briefly, low-
melting-point agar (Difco) was melted and mixed with NBEmedia at a 1:1 ratio
tomake a supporting bottom layer (1%) in a 2ml/well (6-well plate). The bottom
agar layer was allowed to solidify at room temperature for 20min. The top layer
containing 0.4% agar (2 ml/well) was prepared by mixing stock agar solutions
with 100,000 cells in NBE media and then laid on top of the supporting agar
layer. Growth factors were added every 2 days. Cell colonies were allowed
to form at 37C for 2–3 weeks. More than three wells were prepared for the
each condition, and colonies in each well were counted.
Limiting Dilution Assay
In vitro NBE-cultured cells and xenograft-derived tumor cells were dissociated
into single-cell suspensions, sorted for SSEA-1 expression, and then plated
into 96-well plates with various seeding densities (5–50 cells per well). Cells
were incubated at 37C for 2–3 weeks. At the time of quantification, each
well was examined for the formation of tumor spheres.
PCNA Staining and Cell-Cycle Analysis
In vitro NBE-cultured cells and xenograft-derived tumor cells were prepared as
single-cell suspensions and labeled with anti-SSEA-1-FITC antibody (BD) for
surface antigen labeling. The cells were fixed with methanol for 30 min at
20C, permeabilized, and then stained with anti-PCNA antibody (Chemicon)
followed by anti-mouse IgG-PE secondary antibody (BD). For cell-cycle anal-
ysis, cells were incubated in DAPI (40,6-diamidino-2-phenylindole) (Invitrogen)
and analyzed by flow cytometry.
Antibodies for Western Blot Analysis and Immunohistochemistry
The following antibodies were used as primary antibodies: CD133 (Abcam);
Nestin and Sox2 (R &D Systems); Bmi1 (Upstates); Ezh2 (PharMingen);
L1CAM (Neomarker); Olig2 (Santa Cruz Biotechnology; sc-48817); a-tubulin
(Sigma); SSEA-1-FITC (BD); GFAP (Dako); Tuj1 (Covance); and S100b, Integrin
beta1, and Human ribonucleoprotein (Chemicon, 1281).
Lentiviral Vector Preparation
Lentiviruses were produced in 293FT cells with packagingmix (ViraPower Len-
tiviral Expression Systems, Invitrogen) according to the manufacturer’s
instructions. Lentiviruses were concentrated by ultracentrifugation, and viral
titer was determined by serial dilution. pLenti6.2-GW/EmGFP Expression
control vector was purchased from Invitrogen. For the construction of RFP-
expressing lentiviral vector, MaxFP-Red DNA fragment from pMaxFP-Red-C
vector (Amaxa) was inserted into pLenti6.2/V5-DEST Gateway Vector
(Invitrogen).450 Cell Stem Cell 4, 440–452, May 8, 2009 ª2009 Elsevier Inc.Lineage Tracking
We have used both genetic labeling and nongenetic labeling methods for
lineage-tracking experiments. TSCs/TICs derived from various GBMs were
genetically labeled using lentiviral vectors expressing either RFP or GFP (multi-
plicity of infection, 5) and further sorted to ensure uniform labeling. SSEA-1+
(RFP) and SSEA-1 (GFP) cells were sorted by using SSEA-1 FACS, reconsti-
tuted at the desired ratios, and then cultured in a low-cell density allowing for
clonal expansion. After 2 weeks of culture, the remaining cells were examined
for GFP/RFP expression by fluorescent microscope, and the resulting tumor
spheres were counted. These tumor spheres were dissociated into single cells
for FACS analysis and cultured again for secondary tumor sphere formation
assay.
For nongenetic labeling of tumor cells, SSEA-1+ and SSEA-1 cells were
sorted using magnetic beads and labeled with green color dye (CellTracker
Green CMFDA, Invitrogen). Labeled SSEA-1+ or SSEA-1 cells were mixed
with unlabeled SSEA-1 or SSEA-1+ populations, respectively, at a 4:6
(SSEA-1+:SSEA-1) ratio. At each time point during the 5 day culture period,
cells were stained with SSEA-1-PE antibody, and the labeled cells were
detected by using flow cytometry.
Intracranial Tumor Cell Injection into SCID Mice
An intracranial orthotopic model was utilized for evaluation of TIC tumorige-
nicity (Uchida et al., 2000). Unsorted or sorted SSEA-1+ and SSEA-1 cells
were resuspended in 2 ml of HBSS and injected stereotactically into the lateral
ventricles of cryoanesthetized neonatal SCID mice at postnatal day 1 or into
the striatum of adult mice by using stereotactic device (coordinates, 2 mm
anterior, 2 mm lateral, 2.5 mm depth from the dura). Following injection,
neonatal mice were returned to their mothers and allowed to grow to adult-
hood. There was no injection procedure-related animal lethality. The animals
were killed at given time points for the analysis of tumor histology and immu-
nohistochemistry. Brains were perfused with 4% paraformaldehyde by
cardiac perfusion and further fixed at 4C overnight.
Statistical Analysis
All values are shown as mean ± standard deviation (SD). Kaplan-Maier survival
analysis was performed in Prism 4.0 software.
SUPPLEMENTAL DATA
The Supplemental Data include six figures and can be found with this
article online at http://www.cell.com/cell-stem-cell/supplemental/S1934-
5909(09)00104-0.
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